Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process

Infliximab (IFX) is an intravenously administered monoclonal antibody antagonizing the effects of tumor necrosis factor-alpha (TNF) systemically and is efficacious in the treatment of inflammatory bowel disease (IBD). However, studies suggest that the anti-inflammatory effects result from local immu...

Full description

Bibliographic Details
Main Authors: Bahez Gareb, Silke Posthumus, Max Beugeling, Pauline Koopmans, Daan J. Touw, Gerard Dijkstra, Jos G.W. Kosterink, Henderik W. Frijlink
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Pharmaceutics
Subjects:
ColoPulse
infliximab
drug targeting
topical
ileo-colonic
inflammatory bowel disease
Online Access:https://www.mdpi.com/1999-4923/11/9/428

Internet

https://www.mdpi.com/1999-4923/11/9/428

Similar Items